IN8bio (INAB) 10-Q 12 May 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 07, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Registrant Name	IN8BIO, INC.
Entity Central Index Key	0001740279
Entity Tax Identification Number	82-5462585
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity File Number	001-39692
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	350 5th Avenue
Entity Address, Address Line Two	Suite 5330
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10118
City Area Code	646
Local Phone Number	600-6438
Trading Symbol	INAB
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		29,750,348
Document Quarterly Report	true
Document Transition Report	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash	$ 10,860,000	$ 18,182,000
Prepaid expenses and other current assets	3,542,000	4,052,000
Total Current Assets	14,402,000	22,234,000
Non-current assets
Property and equipment, net	4,198,000	4,397,000
Construction In progress	45,000	29,000
Restricted cash	253,000	252,000
Right-of-use assets - finance leases	1,503,000	1,691,000
Right of use assets - operating leases	4,022,000	4,181,000
Other non-current assets	255,000	255,000
Total Non-Current Assets	10,276,000	10,805,000
Total Assets	24,678,000	33,039,000
Current liabilities
Accounts payable	870,000	2,091,000
Accrued expenses and other current liabilities	1,492,000	2,342,000
Short-term finance lease liability	654,000	682,000
Short-term operating lease liability	732,000	707,000
Total Current Liabilities	3,748,000	5,822,000
Long-term finance lease liability	664,000	811,000
Long-term operating lease liability	3,478,000	3,674,000
Total Non-Current Liabilities	4,142,000	4,485,000
Total Liabilities	7,890,000	10,307,000
Stockholders' Equity
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at March 31, 2023 and December 31, 2022, respectively. No shares issued and outstanding	0	0
Common stock, par value $0.0001 per share; 490,000,000 shares authorized at March 31, 2023 and December 31, 2022; 24,960,869 and 24,545,157 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	3,000	3,000
Additional paid-in capital	85,522,000	83,941,000
Accumulated deficit	(68,737,000)	(61,212,000)
Total Stockholders' Equity	16,788,000	22,732,000
Total Liabilities and Stockholders' Equity	$ 24,678,000	$ 33,039,000

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, per share	$ 0.0001	$ 0.0001
Preferred stock shares authorised	10,000,000	10,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	490,000,000	490,000,000
Common stock, shares, issued	24,960,869	24,545,157
Common stock, shares, outstanding	24,960,869	24,545,157

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 4,385	$ 2,381
General and administrative	3,470	3,764
Total operating expenses	7,855	6,145
Other Income	330	0
Loss from operations	(7,525)	(6,145)
Net loss	$ (7,525)	$ (6,145)
Net loss per share attributable to common stockholders - basic	$ (0.30)	$ (0.33)
Net loss per share attributable to common stockholders - diluted	$ (0.30)	$ (0.33)
Weighted-average number of shares used in computing net loss per common share, basic	24,732,580	18,800,546
Weighted-average number of shares used in computing net loss per common share, diluted	24,732,580	18,800,546

Condensed Statements of Convert

Condensed Statements of Convertible Preferred Stock, Common Stock and Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Shares beginning at Dec. 31, 2021		18,781,242
Balance beginning at Dec. 31, 2021	$ 38,183	$ 2	$ 70,872	$ (32,691)
Conversion of convertible preferred stock to common stock, shares		31,025
Conversion of convertible preferred stock to common stock	33		33
Stock-based compensation expense	764		764
Net loss	(6,145)			(6,145)
Shares ending at Mar. 31, 2022		18,812,267
Balance ending at Mar. 31, 2022	32,835	$ 2	71,669	(38,836)
Shares beginning at Dec. 31, 2022		24,545,157
Balance beginning at Dec. 31, 2022	22,732	$ 3	83,941	(61,212)
Stock issued during period shares new issues, amount	722		722
Stock issued during period shares new issues, shares		415,712
Stock-based compensation expense	859		859
Net loss	(7,525)			(7,525)
Shares ending at Mar. 31, 2023		24,960,869
Balance ending at Mar. 31, 2023	$ 16,788	$ 3	$ 85,522	$ (68,737)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities
Net loss	$ (7,525,000)	$ (6,145,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	243,000	16,000
Non-cash stock-based compensation	859,000	764,000
Amortization of financing lease right-of-use assets	188,000	149,000
Amortization of operating lease right-of-use assets	159,000	67,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	510,000	792,000
Accounts payable	(1,035,000)	158,000
Accrued expenses and other current liabilities	(667,000)	(351,000)
Short-term operating lease liabilities	25,000	72,000
Long-term operating lease liabilities	(196,000)	(81,000)
Net cash used in operating activities	(7,439,000)	(4,559,000)
Investing activities
Purchases of property and equipment	(371,000)	(8,000)
Construction in progress	(58,000)	(245,000)
Net cash used in investing activities	(429,000)	(253,000)
Financing activities
Proceeds from the issuance of common stock, net of offering costs	722,000	0
Principal payments on financing leases	(175,000)	(135,000)
Exercise of common stock options	0	33,000
Net cash used in financing activities	547,000	(102,000)
Net increase in cash and restricted cash	(7,321,000)	(4,914,000)
Cash and restricted cash at beginning of period	18,434,000	37,272,000
Cash and restricted cash at end of period	11,113,000	32,358,000
Cash, end of period	10,860,000	32,107,000
Restricted cash, end of period	253,000	251,000
Cash and restricted cash, end of period	$ 11,113,000	$ 32,358,000

Organization and Nature of Oper

Organization and Nature of Operations	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	1. ORGANIZATION AND NATURE OF OPERATIONS Organization and Business IN8bio, Inc. (the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. The Company’s lead product candidates are currently in Phase 1 clinical trials: INB-200, for the treatment of patients with newly diagnosed glioblastoma (“GBM”), and INB-100, for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (“HSCT”). In addition, the Company is currently preparing to initiate patient enrollment in the company-sponsored Phase 2 clinical trial of INB-400 in which autologous genetically modified gamma-delta T cells will be assessed in newly diagnosed GBM patients. With additional funding, the Company is expecting to submit its company-sponsored investigational new drug application (“IND”) and initiate its Phase 1b clinical trial of INB-410 in which allogeneic genetically modified gamma-delta T cells will be assessed in both relapsed and newly diagnosed GBM patients in late 2023. The Company’s DeltEx platform has yielded a broad portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing GBM and other solid tumor types. Incysus, Inc. (“Incysus”) was a corporation formed in the State of Delaware on November 23, 2015 and Incysus, Ltd. was incorporated in Bermuda on February 8, 2016. Incysus was the wholly owned United States subsidiary of Incysus, Ltd. On May 7, 2018, Incysus, Ltd. reincorporated in the United States in a domestication transaction (the “Domestication”) in which Incysus, Ltd. converted into a newly formed Delaware corporation, Incysus Therapeutics, Inc. (“Incysus Therapeutics”). On July 24, 2019, Incysus Therapeutics merged with Incysus. Incysus Therapeutics subsequently changed its name to IN8bio, Inc. in August 2020. Following the Domestication in May 2018 and the merging of Incysus Therapeutics and Incysus in July 2019, the Company does not have any subsidiaries to consolidate. The Company is headquartered in New York, New York. Going Concern To date, the Company has funded its operations primarily with proceeds from various public and private offerings of its common and preferred stock. The Company has incurred recurring losses and negative operating cash flows since its inception, including net losses of $ 7.5 million and $ 6.1 million for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, the Company had an accumulated deficit of $ 68.7 million. On August 16, 2022, the Company completed an underwritten public offering of 5,394,737 shares of its common stock at a public offering price of $ 1.90 per share, for net proceeds of approximately $ 9.0 million, after deducting underwriting discounts, commissions and offering expenses. On August 19, 2022, the underwriter partially exercised their option to purchase an additional 268,949 shares at the public offering price of $ 1.90 per share, resulting in additional net proceeds of approximately $ 0.4 million, after deducting underwriting discounts, commissions and offering expenses, increasing the aggregate net proceeds from the offering to approximately $ 9.4 million. In November 2022, the Company filed a shelf registration statement on Form S-3 (File No. 333-268288) (the “Shelf Registration Statement”) with the Securities and Exchange Commission (“SEC”), which permits the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $ 200 million of its common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, of which $ 50 million of common stock may be issued and sold pursuant to an at-the-market offering program (“ATM”). The Company entered into a Controlled Equity Offering SM sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) and Truist Securities, Inc. (“Truist”) under which Cantor Fitzgerald and Truist agreed to act as sales agents to sell shares of the Company’s common stock, from time to time, through the ATM program. Under current SEC regulations, if at any time the Company's public float is less than $ 75.0 million, and for so long as the Company's public float remains less than $ 75.0 million, the amount the Company can raise through primary public offerings of securities in any 12-month period using shelf registration statements is limited to an aggregate of one-third of the Company's public float, which is referred to as the baby shelf rules. As of March 31, 2023 , the Company's calculated public float was less than $ 75.0 million. During the three months ended March 31, 2023, the Company sold an aggregate of 415,712 shares of common stock under the ATM, resulting in net proceeds of approximately $ 0.7 million, after deducting fees and expenses. Subsequent to March 31, 2023, the Company sold $ 9.9 million in net proceeds, after deducting fees and expenses, pursuant to its ATM program. The Company has not yet generated product sales and as a result has experienced operating losses since inception. The Company expects to incur additional losses in the future as it advances its product candidates through clinical trials, seeks to expand its product candidate portfolio through developing additional product candidates, grows its clinical, regulatory and quality capabilities, and incurs costs associated with operating as a public company, and, based on the Company’s business strategy, its existing cash of $ 10.9 million as of March 31, 2023, and the net proceeds of $ 9.9 million raised through the ATM program subsequent to March 31, 2023 will not be sufficient to fund the Company’s projected operating expenses and capital expenditure requirements beyond February 2024. Accordingly, there is substantial doubt about the Company’s ability to continue to operate as a going concern. To continue to fund the operations of the Company beyond this time period, management has developed plans, which primarily consist of raising additional capital through some combination of public equity offerings, including through ATM offerings, and identifying strategic collaborations, licensing or other arrangements to support development of the Company’s product candidates. There is no assurance, however, that any additional financing or any revenue-generating collaboration will be available when needed, that management of the Company will be able to obtain financing or enter into a collaboration on terms acceptable to the Company, or that any additional financing or revenue generated through third party collaborations will be sufficient to fund our operations through this time period. If additional capital is not available, the Company will have to significantly delay, scale back or discontinue research and development programs or future commercialization efforts. The actual amount of cash that the Company will need to operate is subject to many factors. The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies The Company’s significant accounting policies, which are disclosed in the audited financial statements for the year ended December 31, 2022 and the notes thereto, are included in the Company’s Annual Report on Form 10-K (the “Annual Report”) that was filed with the Securities and Exchange Commission (“SEC”) on March 30, 2023. Since the date of that filing, there have been no material changes to the Company’s significant accounting policies. Basis of Presentation The Company has prepared the accompanying condensed financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”). Un audited Interim Financial Information The condensed financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these condensed financial statements, as is permitted by such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements and notes thereto in the Company's Annual Report. The results for any interim period are not necessarily indicative of results for any future period. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included. Use of Estimates The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting periods presented. Such estimates and assumptions are used for, but are not limited to, the accrual of research and development expenses, deferred tax assets and liabilities and related valuation allowance, stock-based compensation, and the useful lives of property and equipment. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Concentration of Credit Risk Financial instruments that potentially expose the Company to significant concentrations of credit risk consist primarily of cash. All of the Company’s cash is deposited in accounts with major financial institutions. Such deposits are in excess of the federally insured limits. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Significant replacements and improvements are capitalized, while maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. The estimated useful lives of the Company’s respective assets are as follows: Estimated Useful Life Furniture 5 years Machinery and equipment 3 - 5 years Software 3 years Leasehold Improvements The shorter of the useful life of the leasehold improvement or the remaining term of the lease Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated and amortized in accordance with the above guidelines once placed into service. Upon retirement or disposal of property and equipment, the cost and related accumulated depreciation and amortization are removed from the balance sheet and any gain or loss is reflected in the statement of operations. Recently Issued Accounting Standards Updates The Company did not adopt any new accounting guidance during the three months ended March 31, 2023 and as of the date of this report that had a material impact on the financial statements or disclosures. Additionally, there is no pending accounting guidance that the Company expects to have a material impact on the financial statements.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	3. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consist of the following (in thousands): March 31, December 31, Prepaid research and development $ 2,225 $ 2,562 Prepaid insurance 716 1,258 Other 601 232 Total prepaid expenses and other current assets $ 3,542 $ 4,052

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	4. PROPERTY AND EQUIPMENT, NET Property and equipment, net consist of the following (in thousands): March 31, December 31, Machinery and equipment $ 364 $ 358 Furniture and fixtures 370 335 Software 126 126 Leasehold improvements 3,902 3,899 Less accumulated depreciation and amortization ( 564 ) ( 321 ) Property and equipment, net $ 4,198 $ 4,397 Depreciation and amortization expense was $ 243,000 and $ 16,000 for the three months ended March 31, 2023 and 2022 , respectively.

Construction in Progress

Construction in Progress	3 Months Ended
	Mar. 31, 2023
Public Utilities, Property, Plant and Equipment, Plant in Service [Abstract]
Construction in Progress	5. CONSTRUCTION IN PROGRESS Construction in progress consists of the following (in thousands): March 31, December 31, Furniture $ — $ 29 Internal use software not yet in service 45 — Total construction in progress $ 45 $ 29

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of the following (in thousands): March 31, December 31, Accrued clinical trials $ 559 $ 253 Accrued compensation 422 1,460 Accrued legal 104 211 Accrued other 407 418 Total accrued expenses and other current liabilities $ 1,492 $ 2,342

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Stockholders' Equity	7. STOCKHOLDERS' EQUITY The Company’s authorized capital stock consists of 500,000,000 shares, all with a par value of $ 0.0001 per share, of which 490,000,000 shares are designated as common stock and 10,000,000 shares are designated as preferred stock. There were no shares of preferred stock outstanding as of March 31, 2023 and December 31, 2022 , respectively.

Convertible Preferred Stock and

Convertible Preferred Stock and Stockholders' Equity	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stockholders' Equity	7. STOCKHOLDERS' EQUITY The Company’s authorized capital stock consists of 500,000,000 shares, all with a par value of $ 0.0001 per share, of which 490,000,000 shares are designated as common stock and 10,000,000 shares are designated as preferred stock. There were no shares of preferred stock outstanding as of March 31, 2023 and December 31, 2022 , respectively.

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	8. STOCK-BASED COMPENSATION 2018 Equity Incentive Plan On May 7, 2018, the Company established and adopted the 2018 Equity Incentive Plan (the “2018 Plan”) providing for the granting of stock awards for employees, directors and consultants to purchase shares of the Company’s common stock. Upon the effectiveness of the 2020 Plan (as defined below), the 2018 Plan was terminated and no further issuances were made under the 2018 Plan, although it continues to govern the terms of any equity grants that remain outstanding under the 2018 Plan. 2020 Equity Incentive Plan The 2020 Equity Incentive Plan (the “2020 Plan”) was approved by the Board of Directors and the Company’s stockholders and became effective on July 29, 2021. The Board of Directors, or a committee thereof, is authorized to administer the 2020 Plan. The 2020 Plan provides for the grant of incentive stock options (“ISOs”) within the meaning of Section 422 of the U.S. Internal Revenue Code of 1986, (the “IRC”) as amended, to employees, and for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants and any affiliates’ employees and consultants. The number of shares initially reserved for issuance under the 2020 Plan was 4,200,000 , which automatically increases on January 1 of each year for a period of 10 years , beginning on January 1, 2022 and continuing through January 1, 2031, in an amount equal to 5 % of the total number of shares of common stock outstanding on the last day of the immediately preceding year, or a lesser number of shares determined by the Board of Directors no later than the last day of the immediately preceding year. The maximum number of shares of common stock that may be issued upon the exercise of ISOs under the 2020 Plan will be 13,000,000 shares. On January 1, 2023, the shares reserved for issuance was increased by 1,227,257 shares. As of March 31, 2023, 2,355,050 shares were available for grant pursuant to the 2020 Plan. 2020 Employee Stock Purchase Plan The 2020 Employee Stock Purchase Plan (the “2020 ESPP”) was approved by the Company’s Board of Directors and the Company’s stockholders and became effective on July 29, 2021. A total of 200,000 shares of common stock were initially reserved for issuance under this plan, which automatically increases on January 1 of each year by the lesser of (i) 1 % of the outstanding number of shares of common stock on the immediately preceding December 31 and (ii) 400,000 , or such lesser number of shares as determined by our Board. The Board acted not to increase the number of shares of common stock reserved for future issuance under the ESPP as of January 1, 2023. As of March 31, 2023 , no shares of common stock had been issued under the 2020 ESPP and 387,812 shares remained available for future issuance under the 2020 ESPP. The first offering period has not yet been decided by the Company’s Board of Directors or designated committee of the Company’s Board of Directors. Stock Option Activity The following is a summary of the stock option award activity during the three months ended March 31, 2023: Number Weighted- Weighted- Aggregate Outstanding at December 31, 2022 4,003,294 $ 4.90 8.28 $ 860 Granted 20,750 2.00 Exercised — — Forfeited ( 169,040 ) 2.27 Outstanding at March 31, 2023 3,855,004 $ 5.00 8.39 $ 51 Exercisable at March 31, 2023 1,503,046 $ 5.86 7.89 $ 35 Options expected to vest as of March 31, 2023 2,351,958 $ 4.45 8.71 $ 16 The weighted-average grant date fair value of options granted during the three months ended March 31, 2023 and 2022 was $ 2.00 and $ 4.10 , respectively. The aggregate intrinsic value is calculated as the difference between the exercise price and the market price of the Company’s common stock at March 31, 2023. Stock-Based Compensation Expense For the three months ended March 31, 2023 and 2022 , the Company utilized the Black-Scholes option-pricing model for estimating the fair value of the stock options. The following table presents the assumptions and the Company’s methodology for developing each of the assumptions used: March 31, March 31, Volatility 91.91 % 87.13 % Expected life (years) 6.08 6.08 Risk-free interest rate 3.99 % 2.01 % Dividend rate — — • Volatility—The Company estimates the expected volatility of its common stock at the date of grant based on the historical volatility of comparable public companies over the expected term. • Expected life—The expected term represents the period that the Company’s stock option grants are expected to be outstanding. The expected term of the options granted to employees and non-employee directors by the Company has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. • Risk-free interest rate—The risk-free rate for periods within the estimated life of the stock award is based on the U.S. Treasury yield curve in effect at the time of grant. • Dividend rate—The assumed dividend yield is based upon the Company’s expectation of not paying dividends in the foreseeable future. Stock-based compensation expense was recorded in the following line items in the condensed statements of operations for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended 2023 2022 Research and development $ 389 $ 294 General and administrative 470 470 Total stock-based compensation expense $ 859 $ 764 No related tax benefits from stock-based compensation expense were recognized for the three months ended March 31, 2023 and 2022. As of March 31, 2023, there was $ 7.2 million in unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of 2.44 years.

License Agreements

License Agreements	3 Months Ended
	Mar. 31, 2023
License Agreements [Abstract]
License Agreements	9. LICENSE AGREEMENTS Emory University, Children’s Healthcare of Atlanta, Inc. and UAB Research Foundation In June 2016, the Company entered into an exclusive license agreement with Emory University, Children’s Healthcare of Atlanta, Inc. and UAB Research Foundation ("UABRF"), as amended from time to time (the “Emory License Agreement”). The Emory License Agreement was amended in October 2017 and July 2020. Under the Emory License Agreement, the Company obtained an exclusive worldwide license under certain immunotherapy related patents and know-how related to gamma-delta T cells developed by Emory University, Children’s Healthcare of Atlanta, Inc. and UABRF’s affiliate, the University of Alabama at Birmingham, to develop, make, have made, use, sell, import and otherwise commercialize products that are covered by such patents or otherwise incorporate or use the licensed technology. Such exclusive license is subject to certain rights retained by these institutions and also the U.S. government. In consideration of the license granted under the Emory License Agreement, the Company paid Emory University a nominal upfront payment. In addition, the Company is required to pay Emory University development milestones totaling up to an aggregate of $ 1.4 million, low-single-digit to mid-single-digit tiered running royalties on the net sales of the licensed products, including an annual minimum royalty beginning on a specified period after the first sale of a licensed product, and a share of certain payments that the Company may receive from sublicenses. In addition, in the event no milestone payments have been paid in certain years, the Company will be required to pay an annual license maintenance fee. The Emory License Agreement also requires the Company to reimburse Emory University for the cost of the prosecution and maintenance of the licensed patents. Pursuant to the Emory License Agreement, the Company is required to use its best efforts to develop, manufacture and commercialize the licensed product, and is obligated to meet certain specified deadlines in the development of the licensed products. The term of the Emory License Agreement will continue until 15 years after the first commercial sale of the licensed product, or the expiration of the relevant licensed patents, whichever is later. The Company may terminate the Emory License Agreement at will at any time upon prior written notice to Emory University. Emory University has the right to terminate the Emory License Agreement if the Company materially breaches the agreement (including failure to meet diligence obligations) and fails to cure such breach within a specified cure period, if the Company becomes bankrupt or insolvent or decides to cease development and commercialization of the licensed product, or if the Company challenges the validity or enforceability of any licensed patents. Exclusive License Agreement with UABRF In March 2016, the Company entered into an exclusive license agreement with UABRF, as amended from time to time (the “UABRF License Agreement”). The Company amended the UABRF License Agreement in December 2016, January 2017, June 2017 and November 2018. Under the UABRF License Agreement, the Company obtained an exclusive worldwide license under certain immunotherapy-related patents related to the use of gamma-delta T cells, certain CAR-T cells and combination treatments for cellular therapies developed by the University of Alabama at Birmingham and owned by UABRF to develop, make, have made, use, sell, import and otherwise commercialize products that are covered by such patents. Such exclusive license is subject to certain rights retained by UABRF and also the U.S. government. In consideration of the license granted under the UABRF License Agreement, the Company paid UABRF a nominal upfront payment and issued 91,250 shares of common stock to UABRF, which were subject to certain antidilution rights. In addition, the Company is required to pay UABRF development milestones totaling up to an aggregate of $ 1.4 million, lump-sum royalties on cumulative net sales totaling up to an aggregate of $ 22.5 million, mid-single-digit running royalties on net sales of the licensed products, low-single-digit running royalties on net sales of the licensed products, and a share of certain non-royalty income that the Company may receive, including from any sublicenses. The UABRF License Agreement also requires the Company to reimburse UABRF for the cost of the prosecution and maintenance of the licensed patents. Pursuant to the UABRF License Agreement, the Company is required to use good faith reasonable commercial efforts to develop, manufacture and commercialize the licensed product. The term of the UABRF License Agreement will continue until the expiration of the licensed patents. The Company may terminate the UABRF License Agreement at will at any time upon prior written notice to UABRF. UABRF has the right to terminate the UABRF License Agreement if the Company materially breaches the agreement and fails to cure such breach within a specified cure period, if the Company fails to diligently undertake development and commercialization activities as set forth in the development and commercialization plan, if the Company underreports its payment obligations or underpays by more than a specified threshold, if the Company challenges the validity or enforceability of any licensed patents, or if the Company becomes bankrupt or insolvent.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	10. NET LOSS PER SHARE Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is the same as basic net loss per share for the periods presented since the effects of potentially dilutive securities are antidilutive given the net loss of the Company. Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share amounts): Three Months Ended 2023 2022 Net loss $ ( 7,525 ) $ ( 6,145 ) Net loss per share—basic and diluted $ ( 0.30 ) $ ( 0.33 ) Weighted-average number of shares used in computing net loss 24,732,580 18,800,546 The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as Three Months Ended 2023 2022 Stock options to purchase common stock 3,870,924 3,013,205

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	11. COMMITMENTS AND CONTINGENCIES Intellectual Property The Company has existing commitments to the licensors of the intellectual property which the Company has licensed. These commitments are based upon certain clinical research, regulatory, financial and sales milestones being achieved. Additionally, the Company is obligated to pay a single-digit royalty on commercial sales on a global basis of licensed products under the Emory License Agreement and the UABRF License Agreement. The royalty term is the later of 15 years from first commercial sale or expiration of the last-to-expire component of the licensed intellectual property. Legal Proceedings The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred costs related to such legal proceedings.

Facility Leases

Facility Leases	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Facility Leases	12. Facility LEASES The Company has historically entered into lease arrangements for its facilities. As of March 31, 2023, the Company had three operating leases with required future minimum payments. In applying the transition guidance under Accounting Standards Update No. 2016-02, Leases , (“ASC 842”), the Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective date. The Company’s leases generally do not include termination or purchase options. Finance Leases The Company entered into an agreement with an equipment leasing company in 2018, which provided up to $ 2.5 million for equipment purchases in the form of sale and leasebacks or direct leases. As of March 31, 2023 , the Company had completed the sale and leaseback for four pieces of equipment and is leasing three other items directly from the leasing company. The terms of the leases are three years and afterwards provide for either annual extensions or an outright purchase of the equipment. The equipment leases require two advance rental payments to be held as security deposits. The security deposits held amounted to approximately $ 255,000 as of each of March 31, 2023 and December 31, 2022 and are included in other non-current assets on the condensed balance sheets. Operating Leases The Company has an operating lease for office space in Birmingham, Alabama, for a 63-month term ending in March 2026, with an option to extend five years . Throughout the term of the lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. The Company has an operating lease for office space in New York, New York, with a term that commenced on September 15, 2021, and continues through March 2027 . Throughout the term of the lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. The Company has identified an embedded lease within the University of Louisville Manufacturing Services Agreement, as the Company has the exclusive use of, and control over, a portion of the manufacturing facility and equipment of the facility during the contractual term of the manufacturing arrangement. The commencement date of the embedded lease was August 4, 2022 and it continues through August 2028. The Company had a build-to-suit lease agreement with a third party to build out the Company's labs in Birmingham, Alabama, which was substantially completed in December 2022. The agreement had a threshold of $ 4.0 million of total costs incurred. The costs incurred and classified as property and equipment, net on the balance sheets were $ 4.1 million as of March 31, 2023. The operating leases require security deposits at the inception of each lease. The security deposits amounted to approximately $ 263,000 and $ 262,000 as of March 31, 2023 and December 31, 2022, respectively. As of March 31, 2023, approximately $ 253,000 was included in restricted cash and $ 10,000 was included in other current assets. As of December 31, 2022, approximately $ 252,000 was included in restricted cash and $ 10,000 was included in other current assets. The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s finance and operating leases for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended 2023 2022 Lease Cost Amortization of finance right-of-use assets $ 188 $ 149 Interest on finance lease liabilities 33 14 Operating lease cost 288 112 Short-term lease cost 116 105 Total lease cost $ 625 $ 380 March 31, Other Lease Information Cash paid for amounts included in the measurement of lease liability – finance leases $ 33 Cash paid for amounts included in the measurement of lease liability – operating leases $ 299 Weighted-average remaining lease term – finance leases 2.07 years Weighted-average remaining lease term – operating leases 4.74 years Weighted-average discount rate – finance leases 9.7 % Weighted-average discount rate – operating leases 12.1 % The following table reconciles the undiscounted cash flows to the operating and finance lease liabilities at March 31, 2023 (in thousands): Finance Leases Operating Leases Remainder of 2023 $ 581 $ 891 2024 566 1,212 2025 302 1,224 2026 — 1,013 2027 — 767 Thereafter — 422 Total lease payment 1,449 5,529 Less: interest 131 1,319 Total lease liabilities 1,318 4,210 Less: short-term lease liability 654 732 Long-term lease liability $ 664 $ 3,478

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Event	13. SUBSEQUENT EVENTS Subsequent to March 31, 2023, the Company sold an aggregate of 4,789,479 shares of common stock under the ATM resulting in net proceeds of approximately $ 9.9 million, after deducting fees and expenses.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies The Company’s significant accounting policies, which are disclosed in the audited financial statements for the year ended December 31, 2022 and the notes thereto, are included in the Company’s Annual Report on Form 10-K (the “Annual Report”) that was filed with the Securities and Exchange Commission (“SEC”) on March 30, 2023. Since the date of that filing, there have been no material changes to the Company’s significant accounting policies.
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying condensed financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”).
Unaudited Interim Financial Information	Un audited Interim Financial Information The condensed financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these condensed financial statements, as is permitted by such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements and notes thereto in the Company's Annual Report. The results for any interim period are not necessarily indicative of results for any future period. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.
Use of Estimates	Use of Estimates The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting periods presented. Such estimates and assumptions are used for, but are not limited to, the accrual of research and development expenses, deferred tax assets and liabilities and related valuation allowance, stock-based compensation, and the useful lives of property and equipment. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially expose the Company to significant concentrations of credit risk consist primarily of cash. All of the Company’s cash is deposited in accounts with major financial institutions. Such deposits are in excess of the federally insured limits.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Significant replacements and improvements are capitalized, while maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. The estimated useful lives of the Company’s respective assets are as follows: Estimated Useful Life Furniture 5 years Machinery and equipment 3 - 5 years Software 3 years Leasehold Improvements The shorter of the useful life of the leasehold improvement or the remaining term of the lease Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated and amortized in accordance with the above guidelines once placed into service. Upon retirement or disposal of property and equipment, the cost and related accumulated depreciation and amortization are removed from the balance sheet and any gain or loss is reflected in the statement of operations.
Recently Issued Accounting Standards Updates	Recently Issued Accounting Standards Updates The Company did not adopt any new accounting guidance during the three months ended March 31, 2023 and as of the date of this report that had a material impact on the financial statements or disclosures. Additionally, there is no pending accounting guidance that the Company expects to have a material impact on the financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Property and Equipment	The estimated useful lives of the Company’s respective assets are as follows: Estimated Useful Life Furniture 5 years Machinery and equipment 3 - 5 years Software 3 years Leasehold Improvements The shorter of the useful life of the leasehold improvement or the remaining term of the lease

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Components of Property and Equipment, Net	Property and equipment, net consist of the following (in thousands): March 31, December 31, Machinery and equipment $ 364 $ 358 Furniture and fixtures 370 335 Software 126 126 Leasehold improvements 3,902 3,899 Less accumulated depreciation and amortization ( 564 ) ( 321 ) Property and equipment, net $ 4,198 $ 4,397

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): March 31, December 31, Prepaid research and development $ 2,225 $ 2,562 Prepaid insurance 716 1,258 Other 601 232 Total prepaid expenses and other current assets $ 3,542 $ 4,052

Construction in Progress (Table

Construction in Progress (Tables)	3 Months Ended
	Mar. 31, 2023
Public Utilities, Property, Plant and Equipment, Plant in Service [Abstract]
Schedule of construction in progress	Construction in progress consists of the following (in thousands): March 31, December 31, Furniture $ — $ 29 Internal use software not yet in service 45 — Total construction in progress $ 45 $ 29

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following (in thousands): March 31, December 31, Accrued clinical trials $ 559 $ 253 Accrued compensation 422 1,460 Accrued legal 104 211 Accrued other 407 418 Total accrued expenses and other current liabilities $ 1,492 $ 2,342

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Award Activity	The following is a summary of the stock option award activity during the three months ended March 31, 2023: Number Weighted- Weighted- Aggregate Outstanding at December 31, 2022 4,003,294 $ 4.90 8.28 $ 860 Granted 20,750 2.00 Exercised — — Forfeited ( 169,040 ) 2.27 Outstanding at March 31, 2023 3,855,004 $ 5.00 8.39 $ 51 Exercisable at March 31, 2023 1,503,046 $ 5.86 7.89 $ 35 Options expected to vest as of March 31, 2023 2,351,958 $ 4.45 8.71 $ 16
Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted	The following table presents the assumptions and the Company’s methodology for developing each of the assumptions used: March 31, March 31, Volatility 91.91 % 87.13 % Expected life (years) 6.08 6.08 Risk-free interest rate 3.99 % 2.01 % Dividend rate — —
Schedule of Stock-based Compensation Expense	Stock-based compensation expense was recorded in the following line items in the condensed statements of operations for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended 2023 2022 Research and development $ 389 $ 294 General and administrative 470 470 Total stock-based compensation expense $ 859 $ 764

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Share	Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share amounts): Three Months Ended 2023 2022 Net loss $ ( 7,525 ) $ ( 6,145 ) Net loss per share—basic and diluted $ ( 0.30 ) $ ( 0.33 ) Weighted-average number of shares used in computing net loss 24,732,580 18,800,546
Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as Three Months Ended 2023 2022 Stock options to purchase common stock 3,870,924 3,013,205

Facility Leases (Tables)

Facility Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Summary of Lease Costs and Other Information to Company's Finance and Operating Liabilities	The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s finance and operating leases for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended 2023 2022 Lease Cost Amortization of finance right-of-use assets $ 188 $ 149 Interest on finance lease liabilities 33 14 Operating lease cost 288 112 Short-term lease cost 116 105 Total lease cost $ 625 $ 380 March 31, Other Lease Information Cash paid for amounts included in the measurement of lease liability – finance leases $ 33 Cash paid for amounts included in the measurement of lease liability – operating leases $ 299 Weighted-average remaining lease term – finance leases 2.07 years Weighted-average remaining lease term – operating leases 4.74 years Weighted-average discount rate – finance leases 9.7 % Weighted-average discount rate – operating leases 12.1 %
Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Financing Lease Liabilities	The following table reconciles the undiscounted cash flows to the operating and finance lease liabilities at March 31, 2023 (in thousands): Finance Leases Operating Leases Remainder of 2023 $ 581 $ 891 2024 566 1,212 2025 302 1,224 2026 — 1,013 2027 — 767 Thereafter — 422 Total lease payment 1,449 5,529 Less: interest 131 1,319 Total lease liabilities 1,318 4,210 Less: short-term lease liability 654 732 Long-term lease liability $ 664 $ 3,478

Organization and Nature of Op_2

Organization and Nature of Operations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands				2 Months Ended	3 Months Ended
	Apr. 01, 2023	Nov. 01, 2022	Aug. 19, 2022	Oct. 16, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Aug. 16, 2022
Organization And Nature Of Operations [Line Items]
Losses from operations					$ 7,525	$ 6,145
Accumulated deficit					(68,737)		$ (61,212)
Cash					10,860	32,107	$ 18,182
Additional purchase common stock shares			268,949
Maximum [Member]
Organization And Nature Of Operations [Line Items]
Public Float					$ 75,000
IPO [Member]
Organization And Nature Of Operations [Line Items]
Aggregate net proceeds from offering			$ 400	$ 9,000
Sale of Stock, Consideration Received on Transaction			$ 400	$ 9,000
Shares issued								5,394,737
Shares issued price per share			$ 1.90					$ 1.90
SEC [Member]
Organization And Nature Of Operations [Line Items]
Proceeds from Issuance of Common Stock		$ 200,000
SEC [Member] | Maximum [Member]
Organization And Nature Of Operations [Line Items]
Public Float		75,000
ATM [Member]
Organization And Nature Of Operations [Line Items]
Sale of shares					415,712
Aggregate net proceeds from offering					$ 700
Net proceeds					9,900
Sale of Stock, Consideration Received on Transaction					700
Proceeds from Issuance of Common Stock		$ 50,000
ATM [Member] | Subsequent Event [Member]
Organization And Nature Of Operations [Line Items]
Sale of shares	4,789,479
Proceeds from Issuance of Common Stock	$ 9,900
ATM [Member] | Maximum [Member]
Organization And Nature Of Operations [Line Items]
Aggregate net proceeds from offering					9,900
Sale of Stock, Consideration Received on Transaction					9,900
Series A Financing
Organization And Nature Of Operations [Line Items]
Losses from operations					(7,500)	$ (6,100)
Accumulated deficit					$ 68,700

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Property and Equipment (Details)	3 Months Ended
	Mar. 31, 2023
Furniture
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Machinery and equipment | Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Machinery and equipment | Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful lives of Leasehold Improvement	The shorter of the useful life of the leasehold improvement or the remaining term of the lease

Prepaid Expenses And Other Cu_3

Prepaid Expenses And Other Current Assets - Schedule of Prepaid expenses and other current assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Research And Development	$ 2,225	$ 2,562
Prepaid Insurance	716	1,258
Other	601	232
Total prepaid expenses and other current assets	$ 3,542	$ 4,052

Property And Equipment, Net - S

Property And Equipment, Net - Schedule of Components of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Less accumulated depreciation	$ (564)	$ (321)
Property and equipment, net	4,198	4,397
Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	126	126
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	364	358
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	370	335
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 3,902	$ 3,899

Property And Equipment, Net - A

Property And Equipment, Net - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 243,000	$ 16,000

Construction in Progress - Sche

Construction in Progress - Schedule of Construction In Progress (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Public Utilities, Property, Plant and Equipment, Plant in Service [Abstract]
Furniture	$ 0	$ 29
Internal use software not yet in service	45	0
Total construction in progress	$ 45	$ 29

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued clinical trials	$ 559	$ 253
Accrued compensation	422	1,460
Accrued legal	104	211
Accrued other	407	418
Total accrued expenses and other current liabilities	$ 1,492	$ 2,342

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		2 Months Ended	3 Months Ended
	Nov. 01, 2022	Oct. 16, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Aug. 19, 2022	Aug. 16, 2022
Class Of Stock [Line Items]
Capital Units, Authorized			500,000,000
Common stock, par value			$ 0.0001		$ 0.0001
Common Stock, Shares Authorized			490,000,000		490,000,000
Preferred Stock, Shares Authorized			10,000,000		10,000,000
Preferred Stock, Shares Outstanding			0	0	0
Proceeds from Issuance Initial Public Offering			$ 722	$ 0
Aggregate of common stock shares issued			24,960,869		24,545,157
Maximum [Member]
Class Of Stock [Line Items]
Public Float			$ 75,000
IPO [Member]
Class Of Stock [Line Items]
Shares issued price per share						$ 1.90	$ 1.90
Proceeds from Issuance Initial Public Offering		$ 9,400
ATM [Member]
Class Of Stock [Line Items]
Sale of shares			415,712
Proceeds from issuance of common stock after deducting underwriting discounts.	$ 50,000
SEC [Member]
Class Of Stock [Line Items]
Proceeds from issuance of common stock after deducting underwriting discounts.	200,000
SEC [Member] | Maximum [Member]
Class Of Stock [Line Items]
Public Float	$ 75,000

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) - USD ($)		3 Months Ended
	Jul. 29, 2021	Mar. 31, 2023	Mar. 31, 2022
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Weighted average grant-date fair value of options granted		$ 2	$ 4.10
Tax benefit from stock based compensation expense		$ 0	$ 0
Weighted-average period over which cost not yet recognized is expected to be recognized		2 years 5 months 8 days
Restricted Stock [Member]
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Share-based payment arrangement, unrecognized stock based compensation cost		$ 7,200,000
2020 Equity Incentive Plan
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Common stock reserved for future issuance		4,200,000
Shares reserved of issuance under the plan increase duration	10 years
Percentage of number of shares of common stock outstanding	5%
Maximum number of shares of common stock issuable	13,000,000
Share-based payment award, number of shares available for grant		2,355,050
2020 Equity Incentive Plan | January 1, 2022
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Common stock reserved for future issuance		1,227,257
2020 Employee Stock Purchase Plan
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Share-based payment award, shares issued in period		0
Common stock reserved for future issuance	200,000
Percentage of number of shares of common stock outstanding	1%
Maximum number of shares of common stock issuable	400,000
Share-based payment award, number of shares available for grant		387,812

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Stock Option Award Activities (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Options outstanding, beginning balance	4,003,294
Options granted	20,750
Options forfeited	(169,040)
Options outstanding, ending balance	3,855,004	4,003,294
Options Exerciseable	1,503,046
Options vested or expected to vest	2,351,958
Options outstanding, weighted average exercise price, beginning balance	$ 4.90
Options granted, weighted average exercise price	2
Options forfeited, weighted average exercise price	(2.27)
Options outstanding, weighted average exercise price, ending balance	5	$ 4.90
Options exercisable, weighted average exercise price	5.86
Options vested or expected to vest, weighted average exercise price	$ 4.45
Options outstanding, weighted average remaining contractual term	8 years 4 months 20 days	8 years 3 months 10 days
Options exercisable, weighted average remaining contractual term	7 years 10 months 20 days
Options vested or expected to vest, weighted average remaining contractual term	8 years 8 months 15 days
Options outstanding, aggregate intrinsic value	$ 51	$ 860
Options vested or expected to vest, aggregate intrinsic value	16
Options exercisable, aggregate intrinsic value	$ 35

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility	91.91%	87.13%
Expected life (years)	6 years 29 days	6 years 29 days
Risk-free interest rate	3.99%	2.01%

Stock-based Compensation - Sc_2

Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 859	$ 764
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	389	294
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 470	$ 470

License Agreements - Additional

License Agreements - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Common stock, shares, issued	24,960,869	24,545,157
Emory License Agreement [Member] | UABRF [Member]
License agreement description	The term of the Emory License Agreement will continue until 15 years after the first commercial sale of the licensed product, or the expiration of the relevant licensed patents, whichever is later.
Milestone payment	$ 1.4
Exclusive License Agreement [Member] | UABRF [Member]
Common stock, shares, issued	91,250
Royalties on cumulative net sales	$ 22.5
Exclusive License Agreement [Member] | UABRF [Member] | Maximum
Milestone payment	$ 1.4

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share [Abstract]
Net loss	$ (7,525)	$ (6,145)
Net loss per share - basic	$ (0.30)	$ (0.33)
Net loss per share - diluted	$ (0.30)	$ (0.33)
Weighted Average Number of Shares Outstanding, Basic	24,732,580	18,800,546
Weighted Average Number of Shares Outstanding, Diluted	24,732,580	18,800,546

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock Options To Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from calculation of diluted net loss per share	3,870,924	3,013,205

Commitments and Contingencies (

Commitments and Contingencies (Additional Information) (Details)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Royalty term	15 years

Facility Leases - Additional In

Facility Leases - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Loss Contingencies [Line Items]
Agreement Threshold	$ 625,000	$ 380,000
Restricted Cash	253,000		$ 252,000
Other Assets, Current	601,000		232,000
Other non-current assets	255,000		255,000
Construction in progress	45,000		29,000
Birmingham, Alabama
Loss Contingencies [Line Items]
Other Assets, Current	10,000		10,000,000
Construction in progress	$ 4,100,000
New York [Member]
Loss Contingencies [Line Items]
Lease expiration month and year	2027-03
Office Building | Birmingham, Alabama
Loss Contingencies [Line Items]
Operating lease, term of contract	63 months
Operating lease, option to extend	option to extend five years
Maximum
Loss Contingencies [Line Items]
Agreement Threshold	$ 4,000,000
Minimum | Birmingham, Alabama
Loss Contingencies [Line Items]
Security deposit	$ 263,000		262,000
Machinery and equipment
Loss Contingencies [Line Items]
Leaseback transaction, description	Company had completed the sale and leaseback for four pieces of equipment and is leasing three other items directly from the leasing company. The terms of the leases are three years and afterwards provide for either annual extensions or an outright purchase of the equipment.
Security deposit	$ 255,000		$ 255,000
Machinery and equipment | Maximum
Loss Contingencies [Line Items]
Amount held for equipment purchases	$ 2,500,000

Facility Leases - Summary of Le

Facility Leases - Summary of Lease Costs and Other Information to Company's Finance and Operating Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Lease Cost
Amortization of finance right-of-use assets	$ 188	$ 149
Interest on finance lease liabilities	33	14
Operating lease cost	288	112
Short-term lease cost	116	105
Total lease cost	625	$ 380
Cash paid for amounts included in the measurement of lease liability – finance leases	33
Cash paid for amounts included in the measurement of lease liability – operating leases	$ 299
Weighted-average remaining lease term – finance leases	2 years 25 days
Weighted-average remaining lease term – operating leases	4 years 8 months 26 days
Weighted-average discount rate – finance leases	9.70%
Weighted-average discount rate – operating leases	12.10%

Facility Leases - Schedule of R

Facility Leases - Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Finance Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Remainder of 2023	$ 581
2024	566
2025	302
Total lease payment	1,449
Less: interest	131
Total lease liability	1,318
Short-term finance lease liability	654	$ 682
Long-term finance lease liability	664	811
Remainder of 2023	891
2024	1,212
2025	1,224
2026	1,013
2027	767
Thereafter	422
Total lease payment	5,529
Less: interest	1,319
Total lease liability	4,210
Short-term operating lease liability	732	707
Long-term operating lease liability	$ 3,478	$ 3,674

Subsequent Event (Additional In

Subsequent Event (Additional Information) (Details) - Atm [Member] - USD ($) $ in Millions			3 Months Ended
	Apr. 01, 2023	Nov. 01, 2022	Mar. 31, 2023
Subsequent Event [Line Items]
Sale of shares			415,712
Proceeds from the issuance of common stock		$ 50
Net proceeds from sale of common stock			$ 0.7
Maximum [Member]
Subsequent Event [Line Items]
Net proceeds from sale of common stock			$ 9.9
Subsequent Event [Member]
Subsequent Event [Line Items]
Sale of shares	4,789,479
Proceeds from the issuance of common stock	$ 9.9